Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.

Autor: Brown JR; The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Eichhorst B; The Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany., Hillmen P; St. James's University Hospital, Leeds, United Kingdom., Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland., Kaźmierczak M; The Department of Hematology & Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland., Lamanna N; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA., Tam CS; The Alfred Hospital & Monash University, Melbourne, VIC, Australia., Qiu L; The State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Zhou K; The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China., Simkovic M; The Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic, & The First Faculty of Medicine, Charles University, Prague, & the Department of Internal Medicine, Prague, Czech Republic., Mayer J; Hematology & Oncology, Masaryk University & University Hospital, Brno, Czech Republic., Gillespie-Twardy A; Blue Ridge Cancer Care, Roanoke, Virginia, USA., Ferrajoli A; The Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Ganly PS; The Department of Haematology, Christchurch Hospital, Christchurch, New Zealand., Weinkove R; Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, & the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand., Grosicki S; The Department of Hematology & Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland., Mital A; The Department of Hematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland., Robak T; The Medical University of Lodz, Lodz, Poland., Osterborg A; The Department of Oncology-Pathology, Karolinska Institutet, Stockholm & the Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Yimer HA; Texas Oncology-Tyler, US Oncology Network, Tyler, Texas, USA., Salmi T; BeiGene International GmbH, Basel, Switzerland., Wang MD; BeiGene USA, San Mateo, California, USA., Fu L; Formerly of BeiGene., Li J; BeiGene (Beijing), Beijing, China., Wu K; BeiGene USA, San Mateo, California, USA., Cohen A; BeiGene USA, San Mateo, California, USA., Shadman M; The Fred Hutchinson Cancer Center & the Department of Medicine, University of Washington, Seattle, USA.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 717-726. Date of Electronic Publication: 2023 Dec 13.
DOI: 10.2217/fon-2023-0849
Databáze: MEDLINE